In addition, SGLT-2 inhibitors can decrease plasma triglyceride levels and increase high-density lipoprotein which can improve dyslipidemia and be helpful in alleviating hepatic steatosis. This evidence concerns the gene SLC5A2 and metabolic syndrome.